Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 4, 2003, Pages 1355-1363

  Humphrey, William R ^a   Shattuck, Mark H ^a   Zielinski, Raymond J ^a   Kuo, Ming Shang T ^a   Biermacher, John J ^a   Smith, Donald P ^a   Jensen, Jana L ^a   Schaadt, Ronda D ^a   Zurenko, Gary E ^a   Richards, Ivan M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFOTAXIME; LINEZOLID; PENICILLIN G; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; ERADICATION THERAPY; FEMALE; GERBIL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MIDDLE EAR EFFUSION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OTITIS MEDIA; PENICILLIN RESISTANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TANDEM MASS SPECTROMETRY;

ACETAMIDES; ACUTE DISEASE; ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; FEMALE; GERBILLINAE; MICROBIAL SENSITIVITY TESTS; OTITIS MEDIA; OXAZOLIDINONES; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0037378051     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.4.1355-1363.2003     Document Type: Article

References (38)

1. Andes, D., M. L. van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
2. Austrian, R. 1998. Streptococcus pneumoniae, p. 1719-1723. In S. L. Gorbach, J. G. Bartlet, and N. R. Blacklow (ed.), Infectious diseases, 2nd ed. The W. B. Saunders Company, Philadelphia, Pa.
3. Barry, B., M. Muffat-Joly, P. Gehanno, and J.-J. Pocidalo. 1993. Effect of increased dosages of amoxicillin in treatment of experimental middle ear otitis due to penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 37:1599-1603.
4. Bluestone, C. D. 1998. Ear and mastoid infections, p. 530-539. In S. L. Gorbach. J. G. Bartlet, and N. R. Blacklow (ed.), Infectious diseases, 2nd ed. The W. B. Saunders Company, Philadelphia, Pa.
5. Burkhardt, O., K. Borner, N. von der Hbh, P. Köppe, M. W. Pletz, C. E. Nord, and H. Lode. 2002. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J. Antimicrob. Chemother. 50:707-712.
6. Clemett, D., and A. Markham. 2000, Linezolid. Drugs 59:815-827.
7. Conte, J. E., Jr., J. A. Golden, J. Kipps, and E. Zurlinden. 2002. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. 46:1475-1480.
8. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
9. Craig, W. A., and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 15:255-259.
10. Dagan, R. 2000. Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms. Pediatr. Infect. Dis. J. 19:S57-S65.
11. Dagan, R., K. P. Klugman, W. A. Craig, and F. Baquero. 2001. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. 47:129-140.
12. Dailey, C. F., C. L. Dileto-Fang, L. V. Buchanan, M. P. Oramas-Shirey, D. H. Batts, C. W. Ford, and J. K. Gibson. 2001. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2304-2308.
13. Doern, G. V., A. B. Brueggemann, H. Huynh, E. Wingert, and P. Rhomberg. 1999. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-1998. Emerg. Infect. Dis. 5:757-765.
14. Dowell, S. F., J. C. Butler, G. S. Giebink, M. R. Jacobs, D. Jernigan, D. M. Musher, A. Rakowsky, B. Schwartz, and the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. 1999. Acute otitis media: management and surveillance in an era of pneumococcal resistancea report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr. Infect. Dis. J. 18:1-9.
15. Ford, C. W., J. C. Hamel, D. M. Wilson, J. K. Moerman, D. Stapert, R. J. Yancey, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents against experimental bacterial infections. Antimicrob. Agents Chemother. 40:1508-1513.
16. Fulghum, R. S., J. E. Brinn, A. M. Smith, H. J. Daniel III, and P. J. Loesche. 1982. Experimental otitis media in gerbils and chinchillas with Streptococcus pneumoniae, Haemophilus influenzae, and other aerobic and anaerobic bacteria. Infect. Immun. 36:802-1810.
17. Genin, M. J. 2000. Recent progress with oxazolidinone antibacterial agents. Exp. Opin. Ther. Patents 10:1405-1414.
18. Gentry-Nielsen, M. J., K. M. Olsen, and L. C. Preheim. 2002. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob. Agents Chemother. 46:1345-1351.
19. Gordon, C., C. Regamey, and W. M. M. Kirby. 1972. Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Antimicrob. Agents Chemother. 1:504-507.
20. Harrison, C. J., M. I. Marks, and D. F. Welch. 1985. Microbiology of recently treated acute otitis media compared with previously untreated acute otitis media. Pediatr. Infect. Dis. 4:641-646.
21. Jacobs, M. R., S. Bajaksouzian, A. Zilles, G. Lin, G. A. Pankuch, and P. C. Appelbaum. 1999. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study. Antimicrob. Agents Chemother. 43:1901-1908.
22. Jorgensen, J. H., G. V. Doern, L. A. Maher, A. W. Howell, and J. S. Redding. 1989. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 34:2075-2080.
23. Klein, J. O. 2000. Management of otitis media: 2000 and beyond. Pediatr. Infect. Dis. J. 19:383-387.
24. Lin, A. H., R. W. Murray, T. J. Vidmar, and K. R. Marotti. 1997. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob. Agents Chemother. 41:2127-2131.
25. Mason, E. O., Jr., L. B. Lamberth, and S. L. Kaplan. 1996. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:1039-1040.
26. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. NCCLS document M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
27. Pelton, S. I., M. Figuera, R. Albut, and D. Stalker. 2000. Efficacy of linezolid in experimental otitis media. Antimicrob, Agents Chemother. 44:654-657.
28. Pichichero, M. E., and C. L. Pichichero. 1995. Persistent acute otitis media: I. Causative pathogens. Pediatr. Infect. J. 14:178-183.
29. Poole, M. D. 1995. Otitis media complications and treatment failures: implications of pneumococcal resistance, Pediatr, Infect. Dis. J. 14:S23-S26.
30. Rubinstein, E., S. K. Cammarata, T. H. Oliphant, R. G. Wunderink, and the Linezolid Nosocomial Pneumonia Study Group. 2001. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32:402-412.
31. Slatter, J. G., L. A. Adams, E. C. Bush, K. Chiba, P. T. Daley-Yates, K. L. Feenstra, S. Koike, N. Ozawa, G. W. Peng, J. P. Sams, M. R. Schuette, and S. Yamazaki. 2002. Pharmacokinetics, toxicokinetics, distribution, metabolism, and excretion of linezolid in mouse, rat, and dog. Xenobiotica 32:907-924.
32. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1996. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parental agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 40:481-484.
33. Stevens, D. L., L. G. Smith, J. B. Bruss, M. A. McConnell-Martin, S. E. Duvall, W. M. Todd, and B. Hafkin. 2000. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections, Antimicrob. Agents Chemother. 44:3408-3413.
34. Swaney, S. M., H. Aoki, M. C. Ganoza, and D. L. Shinabarger. 1998. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. 42:3251-3255.
35. Teele, D. W., S. I. Pelton, and J. O. Klein. 1981. Bacteriology of acute otitis media unresponsive to initial antimicrobial therapy. J. Pediatr. 98:537-539.
36. Thompson, T. A., D. Gardner, R. S. Fulghum, H. J. Daniel, W. E. Allen, J. M. Worthington, and P. P. Williams. 1981. Indigenous nasopharyngeal, auditory canal, and middle ear bacterial flora of gerbils: animal model for otitis media. Infect. Immun. 32:113-118.
37. Woodnutt, G., V. Berry, and L. Mizen. 1995. Effect of protein binding on penetration of β-lactams into rabbit peripheral lymph. Antimicrob. Agents Chemother. 39:2678-2683.
38. Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilburn, S. E. Glickman, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40:839-845.